Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Belbuca — Product revenues, net

Other product segments

Jornay PM
$46.06M+41.2%
Xtampza ER
$45.01M—
Nucynta ER
$15.72M-21.2%
Symproic and other
$14.45M—
Nucynta IR
$14.36M-45.8%
Azstarys
$12.91M—
Symproic
$3.02M-18.9%
Nucynta ER AG
$2.78M—
Nucynta IR AG
$2.36M—

Similar metrics at other companies

Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$3.33B+13.2%
Vertex Pharmaceuticals logo
VRTXOther CF product revenues — Product revenues, net
$135.9M-12.5%
Vertex Pharmaceuticals logo
VRTXOther revenues — Product revenues, net
$0-100%
Vertex Pharmaceuticals logo
VRTXALYFTREK — Product revenues, net
$573.6M+266%
Vertex Pharmaceuticals logo
VRTXCASGEVY — Product revenues, net
$76.4M+151%
Vertex Pharmaceuticals logo
VRTXJOURNAVX — Product revenues, net
$49.6M+313%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$944.15M-1.3%
Enterprise value$798.74M-3.1%
P/E19.7×-6.7×
P/S1.2×-0.2×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Belbuca$57,669$52,600$110,318$104,258
Xtampza ER45,00652,60595,775100,247
Jornay PM46,05832,62684,95161,165
Nucynta IR14,35626,50140,43453,918
Nucynta ER15,72319,94633,95739,632
Azstarys12,910—12,910—
Symproic3,0203,7227,2136,537
Nucynta ER AG2,775—4,221—

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net?
Collegium Pharmaceutical, Inc. (COLL) reported belbuca — product revenues, net of $57.67M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net changed year-over-year?
Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net increased by 9.6% year-over-year, from $52.6M to $57.67M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net?
Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net has grown at a 20.6% compound annual growth rate (CAGR), from $126.46M to $221.65M.
What does belbuca — product revenues, net mean?
Represents the total net revenue generated from the sale of the Belbuca product line after accounting for returns, allowances, and rebates. This metric is a primary indicator of the product's market adoption and commercial performance within the specialty pharmaceutical portfolio.

Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — product revenues, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude